Verona Pharma plc Verona Pharma Plc: Issue Of Equity And Total Voting Rights

 
TIDMVRP 
 
   LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that it yesterday issued 887,080 
Ordinary Shares of 5 pence each (the "New Ordinary Shares") following 
the vesting of restricted stock units held by former employees in the 
Company, Jan-Anders Karlsson and Piers Morgan. 
 
   Application will be made to the London Stock Exchange for the New 
Ordinary Shares to be admitted to trading on AIM, with dealings expected 
to commence on March 26, 2020 ("Admission"). 
 
   Total voting rights 
 
   Following Admission, the Company will have a total of 106,213,718 
Ordinary Shares in issue each carrying one voting right. The Company 
does not hold any Ordinary Shares in Treasury. This figure of 
106,213,718 Ordinary Shares may be used by shareholders as the 
denominator for the calculations by which they will determine if they 
are required to notify their interest in, or a change to their interest 
in, the share capital of the Company under the FCA's Disclosure and 
Transparency Rules. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                      Tel: +44 (0)20 3283 
                                                       4200 
Victoria Stewart, Director of Communications             info@veronapharma.com 
 
N+1 Singer                                                 Tel: +44 (0)20 3283 
                                                                          4200 
(Nominated Adviser and UK Broker) 
 Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
 Finance) 
 Tom Salvesen (Corporate Broking)

(END) Dow Jones Newswires

March 20, 2020 07:28 ET (11:28 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024